Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOP vs MCOP in Elderly NHL
NCT00002576Phase 3
Key facts
- Status
- Completed
- Start
- Nov 1992
- Countries
- 1
- Sponsor
- CRUK & UCL Cancer Trials Centre
- Modality
- DNA Intercalators/Alkylators
- Drugs
- mitoxantrone
- Conditions
- non-Hodgkin lymphoma (NHL)
01
Overview
Phase 3, randomised, open-label trial of mitoxantrone in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by CRUK & UCL Cancer Trials Centre. Primary endpoints: Treatment-related neurologic toxicity and Treatment-related hematologic toxicity. Started Nov 1992; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
CHOP
Standard CHOP chemotherapy
MCOP
MCOP chemotherapy (Mitoxantrone replaces Doxorubicin)
03
Who it enrols
Elderly patients (65+) with histologically confirmed intermediate- or high-grade non-Hodgkin's lymphoma, no prior chemotherapy or radiotherapy, and sufficient cardiac function for doxorubicin.
04
Endpoints
Primary
Treatment-related neurologic toxicity
Treatment-related hematologic toxicity
Secondary
Survival rate
Beyond the preview
Go deeper on NCT00002576.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002576.